Floatz logo

288 assets in Lymphoma

Therapeutic assets addressing Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
jv-213
Lymphoma
M.D. Anderson Cancer CenterP1CC (43)
LP284
Lymphoma
Lantern Pharma Inc.P1CC (43)
Pomalidomide
Lymphoma
National Cancer Institute (NCI)P1CC (43)
Tak-243
Lymphoma
National Cancer Institute (NCI)P1CC (43)
Enitociclib
Lymphoma
National Cancer Institute (NCI)P1/2CC (42)
Rimiducid
Lymphoma
UNC Lineberger Comprehensive Cancer CenterP1/2CC (42)
azd3470
Lymphoma
AstraZenecaP1/2CC (41)
Blinatumomab
Lymphoma
University of ChicagoP1/2CC (41)
bt02
Lymphoma
Biotroy TherapeuticsP1/2CC (41)
Car-Nk Cell
Lymphoma
Bangdong GongP1/2CC (41)
cts3497
Lymphoma
CytosinLab Therapeutics Co., Ltd.P1/2CC (41)
eb103
Lymphoma
Estrella Biopharma, Inc.P1/2CC (41)
Eliglustat
Lymphoma
Chinese PLA General HospitalP1/2CC (41)
Enoxaparin
Lymphoma
Medical University of GdanskP1/2CC (41)
Ex-Vivo Expanded Γδ T Cell Infusion
Lymphoma
Chinese PLA General HospitalP1/2CC (41)
Fosdesdenosine Sipalabenamide
Lymphoma
NuCana plcP1/2CC (41)
Gecacitinib
Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (41)
hlx301
Lymphoma
Shanghai Henlius BiotechP1/2CC (41)
IM19 CAR-T cells
Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.P1/2CC (41)
mdx2003
Lymphoma
ModeX Therapeutics, An OPKO Health CompanyP1/2CC (41)
Neratinib
Lymphoma
Memorial Sloan Kettering Cancer CenterP1/2CC (41)
ose2101
Lymphoma
OSE ImmunotherapeuticsP1/2CC (41)
Ose-279
Lymphoma
OSE ImmunotherapeuticsP1/2CC (41)
Part A: Ose-279
Lymphoma
OSE ImmunotherapeuticsP1/2CC (41)
Penpulimab
Lymphoma
WEI XUP1/2CC (41)
Pirtobrutinib
Lymphoma
Inhye AhnP1/2CC (41)
Ponatinib
Lymphoma
Incyte Biosciences International SàrlP1/2CC (41)
Repotrectinib
Lymphoma
Turning Point Therapeutics, Inc.P1/2CC (41)
Scri-Car22V2
Lymphoma
Seattle Children's HospitalP1/2CC (41)
Syhx1903
Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.P1/2CC (41)
t3011
Lymphoma
ImmVira Pharma Co. LtdP1/2CC (41)
Valemetostat
Lymphoma
M.D. Anderson Cancer CenterP1/2CC (41)
zg005
Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (41)
dz-002
Lymphoma
Da Zen Theranostics IncP1CC (40)
hlx26
Lymphoma
Shanghai Henlius BiotechP1CC (40)
Anti-Cd19 Car T-Cells
Lymphoma
Affiliated Hospital of Nantong UniversityEarly P1C (39)
Astx 660
Lymphoma
Taiho Oncology, Inc.P1/2C (39)
ibr900 cell
Lymphoma
Beijing Boren HospitalEarly P1C (39)
Ovv-01
Lymphoma
Beijing Boren HospitalEarly P1C (39)
Vic-1911
Lymphoma
Masonic Cancer Center, University of MinnesotaP1/2C (39)
19ucart
Lymphoma
YANRU WANGP1C (37)
Acetylcysteine
Lymphoma
Memorial Sloan Kettering Cancer CenterP1C (37)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells
Lymphoma
Medical College of WisconsinP1C (37)
Atlcar.Cd30.Ccr4 Cells
Lymphoma
UNC Lineberger Comprehensive Cancer CenterP1C (37)
Bms-986403
Lymphoma
Bristol-Myers SquibbP1C (37)
Bpi-371153
Lymphoma
Betta Pharmaceuticals Co., Ltd.P1C (37)
Byon4228
Lymphoma
Byondis B.V.P1C (37)
can2109
Lymphoma
Canwell Biotech LimitedP1C (37)
cd19/baff-r in vivo car-t cell intravenous infusion
Lymphoma
Qi dengP1C (37)
cd19/cd22-bispecific car-t cells
Lymphoma
Seattle Children's HospitalP1C (37)
Showing 201 to 250 of 288 assets
PreviousPage 5 of 6Next